omniture
logo
Search
VISEN SHANGHAI
Media Room

Latest News

rss

VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism

* 77.6% of patients treated with palopegteriparatide in the PaTHway China Trial achieved the prim...

2024-08-12 21:00 1797

VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China

SHANGHAI, March 7, 2024 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceuti...

2024-03-08 10:00 1469

Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial

SHANGHAI, Nov. 16, 2023 /PRNewswire/ -- VISEN Pharmaceuticals (VISEN), an innovative biopharmaceuti...

2023-11-16 22:00 1553